Cutting-Edge Approache to Rare Disease TreatmentFocused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases MELAS and Leigh Syndrome (LS).
MELAS
TTI’s lead product, TTI-0102, targets oxidative stress to treat Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS), a rare disorder affecting 15,000 patients in the U.S. and 20,000 in the EU. The Phase 2 trial, set to launch in early 2025 across the Netherlands and France, will evaluate physical endurance and biomarkers in 12 patients, aiming to provide a breakthrough therapy for this underserved condition.
Leigh Syndrome (LS)
TTI has partnered with a leading U.S. children’s hospital and plans to file an IND to begin a Phase 2a trial in early 2025 for Leigh Syndrome, a severe mitochondrial disease with no current treatment options. Diagnosed in infancy, LS impacts 1 in 40,000 births, with symptoms like motor skill loss and seizures. TTI-0102 offers hope by addressing the underlying oxidative stress.
Targeting critical unmet needs in rare mitochondrial diseases that represent significant opportunities, TTI has a solid foundation for growth as upcoming 2025 cinical trials position TTI for major milestones in biotech innovation.
For more information, refer to this deep dive:
https://x.com/StckMasterFlash/status/1866620308544786857 Posted on Behalf of Thiogenesis Therapeutics Corp.